AssetMark Inc
IBB icon

AssetMark Inc’s iShares Biotechnology ETF IBB Stock Holding History

AssetMark Inc’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Buy
85,289
+8,579
+11% +$1.47M 0.03% 421
2026
Q1 		$13M Buy
76,710
+2,681
+4% +$458K 0.03% 442
2025
Q4 		$12.5M Buy
74,029
+73,980
+150,980% +$12M 0.03% 440
2025
Q3 		$7.07K Buy
49
+6
+14% +$819 ﹤0.01% 2232
2025
Q2 		$5.44K Sell
43
-63
-59% -$7.73K ﹤0.01% 2114
2025
Q1 		$13.6K Sell
106
-74
-41% -$10K ﹤0.01% 1783
2024
Q4 		$23.8K Buy
+180
New +$25.3K ﹤0.01% 1613
2022
Q4 		– Sell
-51
Closed -$6K – 1618
2022
Q3 		$6K Buy
51
+26
+104% +$3.23K ﹤0.01% 1274
2022
Q2 		$3K Buy
+25
New +$2.97K ﹤0.01% 1344
2021
Q2 		– Sell
-67
Closed -$10K – 1421
2021
Q1 		$10K Buy
67
+65
+3,250% +$10.3K ﹤0.01% 930
2020
Q4 		$0 Sell
2
-148
-99% -$21.2K ﹤0.01% 1430
2020
Q3 		$20K Hold
150
– – ﹤0.01% 835
2020
Q2 		$21K Hold
150
– – ﹤0.01% 790
2020
Q1 		$16K Buy
+150
New +$17.3K ﹤0.01% 911
2017
Q4 		– Sell
-21
Closed -$2K – 1987
2017
Q3 		$2K Hold
21
– – ﹤0.01% 1270
2017
Q2 		$2K Hold
21
– – ﹤0.01% 1222
2017
Q1 		$2K Hold
21
– – ﹤0.01% 1134
2016
Q4 		$2K Hold
21
– – ﹤0.01% 1135
2016
Q3 		$2K Sell
21
-147
-88% -$14K ﹤0.01% 1122
2016
Q2 		$14K Sell
168
-465
-73% -$41.7K ﹤0.01% 917
2016
Q1 		$55K Sell
633
-670,257
-100% -$59.9M ﹤0.01% 546
2015
Q4 		$75.7M Sell
670,890
-300,225
-31% -$32.6M 1.4% 18
2015
Q3 		$98.2M Buy
971,115
+440,313
+83% +$52.8M 2.05% 13
2015
Q2 		$65.3M Sell
530,802
-183,762
-26% -$22M 1.36% 22
2015
Q1 		$81.8M Buy
714,564
+316,104
+79% +$34.9M 1.74% 15
2014
Q4 		$40.3M Buy
+398,460
New +$38.7M 0.88% 34
2014
Q3 		– Sell
-23,748
Closed -$2.04M – 486
2014
Q2 		$2.04M Buy
+23,748
New +$1.87M 0.04% 200

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

AssetMark Inc's IBB Position: Q2 2026 in Review

AssetMark Inc increased its iShares Biotechnology ETF (IBB) stake by 11% in Q2 2026, buying an estimated $1.47M and bringing the position to 85,289 shares worth $16.2M. The position accounts for 0.03% of the portfolio, ranked #421.

AssetMark Inc first reported a position in IBB in Q2 2014 and has held it in 27 quarters since. The position peaked at $98.2M in Q3 2015. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • AssetMark Inc held 85,289 shares of iShares Biotechnology ETF worth $16.2M as of Q2 2026.
  • AssetMark Inc bought 8,579 iShares Biotechnology ETF shares in Q2 2026, an estimated $1.47M.
  • iShares Biotechnology ETF made up 0.03% of AssetMark Inc's portfolio in Q2 2026, its #421 holding.
  • AssetMark Inc first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 27 quarters since.
  • AssetMark Inc's iShares Biotechnology ETF position peaked at $98.2M in Q3 2015.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.